OCS Stock Summary and Trading Ideas (Oculis Holding Ag - | NASDAQ:OCS)

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding Ag - trades on the NASDAQ stock market under the symbol OCS.

As of March 6, 2026, OCS stock price declined to $26.96 with 257,069 million shares trading.

OCS has a beta of 0.85, meaning it tends to be less sensitive to market movements. OCS has a correlation of 0.09 to the broad based SPY ETF.

OCS has a market cap of $1.56 billion. This is considered a Small Cap stock.

Last quarter Oculis Holding Ag - reported $514,161 in Revenue and -$.53 earnings per share. This beat revenue expectation by $244,161 and missed earnings estimates by -$.10.

In the last 3 years, OCS traded as high as $30.68 and as low as $6.26.

The top ETF exchange traded funds that OCS belongs to (by Net Assets): SBIO, SMLV, GWX.

OCS has outperformed the market in the last year with a return of +44.1%, while the SPY ETF gained +18.7%. In the last 3 month period, OCS beat the market returning +24.4%, while SPY returned -1.7%. However, in the most recent 2 weeks OCS has underperformed the stock market by returning -7.6%, while SPY returned -2.5%.

OCS support price is $27.06 and resistance is $28.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCS shares will trade within this expected range on the day.